keyword
MENU ▼
Read by QxMD icon Read
search

Clinical trials in ibd

keyword
https://www.readbyqxmd.com/read/29349829/physicians-perspective-on-the-clinical-meaningfulness-of-inflammatory-bowel-disease-trial-results-an-international-organization-for-the-study-of-inflammatory-bowel-disease-ioibd-survey
#1
P Olivera, W J Sandborn, J Panés, C Baumann, G D'Haens, S Vermeire, S Danese, L Peyrin-Biroulet
BACKGROUND: Several novel compounds are being developed for inflammatory bowel diseases (IBD). In addition, biosimilar drugs are being approved. An increasing number of head-to-head, superiority and non-inferiority trials in patients with IBD are expected in the future. The clinical relevance of the magnitude of the effect size is often debated. AIM: To better understand physicians' perspectives on the clinical meaningfulness of IBD trial results. METHODS: We conducted an online survey among all IOIBD (International Organization for the Study of Inflammatory Bowel Diseases) members, asking their opinion on the clinical relevance of the results of IBD trials...
January 19, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29334728/changing-treatment-paradigms-for-the-management-of-inflammatory-bowel-disease
#2
REVIEW
Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
Inflammatory bowel disease (IBD) is a chronic and progressive inf lammatory condition of the gastrointestinal tract causing bowel damage, hospitalizations, surgeries, and disability. Although there has been much progress in the management of IBD with established and evolving therapies, most current approaches have failed to change the natural course. Therefore, the treatment approach and follow-up of patients with IBD have undergone a significant change. Usage of immunosuppressants and/or biologics early during the course of the disease, known as top-down or accelerated step-up approach, was shown to be superior to conventional management in patients who had been recently diagnosed with IBD...
January 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29332708/management-of-psoriasis-in-patients-with-inflammatory-bowel-disease-from-the-medical-board-of-the-national-psoriasis-foundation
#3
REVIEW
Scott M Whitlock, Clinton W Enos, April W Armstrong, Alice Gottlieb, Richard G Langley, Mark Lebwohl, Joseph F Merola, Caitriona Ryan, Michael P Siegel, Jeffrey M Weinberg, Jashin J Wu, Abby S Van Voorhees
BACKGROUND: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. OBJECTIVE: To assess therapeutic options for patients with psoriasis and concurrent IBD. METHODS: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017...
February 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29320910/predicting-and-explaining-inflammation-in-crohn-s-disease-patients-using-predictive-analytics-methods-and-electronic-medical-record-data
#4
Bhargava K Reddy, Dursun Delen, Rupesh K Agrawal
Crohn's disease is among the chronic inflammatory bowel diseases that impact the gastrointestinal tract. Understanding and predicting the severity of inflammation in real-time settings is critical to disease management. Extant literature has primarily focused on studies that are conducted in clinical trial settings to investigate the impact of a drug treatment on the remission status of the disease. This research proposes an analytics methodology where three different types of prediction models are developed to predict and to explain the severity of inflammation in patients diagnosed with Crohn's disease...
January 1, 2018: Health Informatics Journal
https://www.readbyqxmd.com/read/29314065/platelet-rich-fibrin-combined-with-a-porous-hydroxyapatite-graft-for-the-treatment-of-3-wall-intrabony-defects-in-chronic-periodontitis-a-randomized-controlled-clinical-trial
#5
A R Pradeep, Pavan Bajaj, Nishanth S Rao, Esha Agarwal, Savitha B Naik
BACKGROUND: Porous hydroxyapatite (HA) bone grafting material has been used to fill periodontal intrabony defects (IBDs), resulting in clinically acceptable responses. Platelet-rich fibrin (PRF) is a leukocyte and platelet preparation that concentrates various polypeptide growth factors and, therefore, has the potential for use as regenerative treatment for periodontal defects. The present study aims to explore the clinical and radiographic effectiveness of autologous PRF versus PRF + HA in treatment of IBDs in patients with chronic periodontitis...
December 2017: Journal of Periodontology
https://www.readbyqxmd.com/read/29305366/vedolizumab-induced-acute-pancreatitis-the-first-reported-clinical-case
#6
Sherman Picardo, Kenji So, Kannan Venugopal, Marcus Chin
Drug-induced acute pancreatitis (DIAP) is a rare, but clinically significant diagnosis. Vedolizumab, an α4β7 integrin inhibitor, which was approved in 2015 for treatment of moderate to severe inflammatory bowel disease, is a well-tolerated medication with a favourable safety profile and minimal serious adverse events in premarketing clinical trials. We present the first reported case of acute pancreatitis directly attributable to vedolizumab.
January 5, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29298542/the-role-of-alpha7-nicotinic-acetylcholine-receptors-in-inflammatory-bowel-disease-involvement-of-different-cellular-pathways
#7
Mohammad Seyedabadi, Reza Rahimian, Jean-Eric Ghia
Autonomic imbalance plays a pivotal role in the pathophysiology of inflammatory bowel diseases (IBD). The central nervous system (CNS) cooperates dynamically with the immune system to regulate inflammation through humoral and neural pathways. In particular, acetylcholine (Ach), the main neurotransmitter in the vagus nerve, decreases the production of pro-inflammatory cytokines through a mechanism dependent on the α7 nicotinic Ach receptors (α7nAChRs). Areas covered: Here, we review the evidence for involvement of the cholinergic anti-inflammatory pathway (CAP) in IBD...
January 3, 2018: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/29291255/efficient-long-term-depletion-of-cd20-b-cells-by-rituximab-does-not-affect-gut-resident-plasma-cells
#8
Mathieu Uzzan, Huaibin M Ko, Adam K Rosenstein, Kamron Pourmand, Jean-Frederic Colombel, Saurabh Mehandru
The vast majority of antibody-producing B cells are located within the gastrointestinal tract and are key players in maintaining homeostasis. The failure of rituximab, a potent B cell-depleting agent, to ameliorate ulcerative colitis in a single clinical trial has dampened enthusiasm to study B cells in patients with inflammatory bowel disease (IBD). However, several lines of evidence suggest that intestinal B cells may be affected in IBD. Additionally, the pathophysiological mechanisms underlying rituximab's lack of efficacy in IBD remain unclear...
December 31, 2017: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/29288099/diagnosis-and-management-of-peristomal-pyoderma-gangrenosum-a-systematic-review
#9
REVIEW
Ladan Afifi, Isabelle M Sanchez, Matthew M Wallace, Sara F Braswell, Alex G Ortega-Loayza, Kanade Shinkai
BACKGROUND: Peristomal pyoderma gangrenosum (PPG) is an uncommon subtype of pyoderma gangrenosum. PPG is a challenging condition to diagnose and treat; no evidence-based guidelines exist. OBJECTIVE: To identify important clinical features of PPG and effective treatments available for its management. METHODS: A systematic literature review of PPG was performed using PubMed, Medline, and Embase databases. RESULTS: We describe 335 patients with PPG from 79 studies...
December 26, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29259715/clinical-trials-using-mesenchymal-stem-cells-in-liver-diseases-and-inflammatory-bowel-diseases
#10
REVIEW
Atsunori Tsuchiya, Yuichi Kojima, Shunzo Ikarashi, Satoshi Seino, Yusuke Watanabe, Yuzo Kawata, Shuji Terai
Mesenchymal stem cell (MSC) therapies have been used in clinical trials in various fields. These cells are easily expanded, show low immunogenicity, can be acquired from medical waste, and have multiple functions, suggesting their potential applications in a variety of diseases, including liver disease and inflammatory bowel disease. MSCs help prepare the microenvironment, in response to inflammatory cytokines, by producing immunoregulatory factors that modulate the progression of inflammation by affecting dendritic cells, B cells, T cells, and macrophages...
2017: Inflammation and Regeneration
https://www.readbyqxmd.com/read/29258369/high-treatment-persistence-rate-and-significant-endoscopic-healing-among-real-life-patients-treated-with-vedolizumab-a-finnish-nationwide-inflammatory-bowel-disease-cohort-study-finvedo
#11
Tero Ylisaukko-Oja, Jaakko Aaltonen, Heikki Nuutinen, Timo Blomster, Airi Jussila, Markku Pajala, Kimmo Salminen, Veikko Moilanen, Kalle Hakala, Mikko Kellokumpu, Kari Toljamo, Henna Rautiainen, Juha Kuisma, Markku Peräaho, Pauliina Molander, Jouni Silvennoinen, Ville Liukkonen, Hans Henricson, Jyrki Tillonen, Mirva Esterinen, Christian Nielsen, Eija Hirsi, Margus Lääne, Ulla-Maija Suhonen, Ilkka Vihriälä, Petri Mäkelä, Mika Puhto, Jari Punkkinen, Hannu Sulonen, Sauli Herrala, Jari Jokelainen, Klaus Tamminen, Taina Sipponen
OBJECTIVES: The efficacy and tolerability of vedolizumab in the treatment of inflammatory bowel diseases (IBD) has been demonstrated in an extensive GEMINI clinical trial programme. Clinical trials represent highly selected patient populations and, therefore, it is important to demonstrate effectiveness in real-life clinical practice. We set out to assess real-world treatment outcomes of vedolizumab in a nationwide cohort of treatment refractory Finnish Crohn's disease (CD) and ulcerative colitis (UC) patients...
December 19, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29228230/the-efficacy-of-home-telemonitoring-versus-conventional-follow-up-a-randomised-controlled-trial-among-teenagers-with-inflammatory-bowel-disease
#12
Anke Heida, Alie Dijkstra, Anneke Muller Kobold, John Rossen, Angelika Kindermann, Freddy Kokke, Tim de Meij, Obbe Norbruis, Rinse Weersma, Margreet Wessels, Thalia Hummel, Hankje Escher, Herbert van Wering, Daniëlle Hendriks, Luisa Mearin, Henk Groen, Henkjan Verkade, Patrick van Rheenen
Background and aims: Conventional follow-up of teenagers with inflammatory bowel diseases (IBD) is done during scheduled outpatient visits regardless of how well the patient feels. We designed a telemonitoring strategy for early recognition of flares and compared its efficacy with conventional follow-up. Methods: Multicentre randomised trial in patients aged 10-19 years with IBD in clinical remission at baseline. Participants assigned to telemonitoring received automated alerts to complete a symptom score and send a stool sample for calprotectin measurement...
December 8, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29223139/novel-treatments-for-inflammatory-bowel-disease
#13
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
Increased understanding of the immunopathology of inflammatory bowel disease (IBD) has led to the development of targeted therapies and has unlocked a new era in IBD treatment. The development of treatment options aimed at a variety of pathological mechanisms offers new hope for customized therapies. Beyond anti-tumor necrosis factor agents, selective lymphocyte trafficking inhibitors have been proposed as potent drugs for IBD. Among these, vedolizumab has recently been approved for both Crohn's disease and ulcerative colitis...
December 11, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29206211/the-imbalance-between-n-6-n-3-polyunsaturated-fatty-acids-and-inflammatory-bowel-disease-a-comprehensive-review-and-future-therapeutic-perspectives
#14
REVIEW
Eleonora Scaioli, Elisa Liverani, Andrea Belluzzi
Eating habits have changed dramatically over the years, leading to an imbalance in the ratio of n-6/n-3 polyunsaturated fatty acids (PUFAs) in favour of n-6 PUFAs, particularly in the Western diet. Meanwhile, the incidence of inflammatory bowel disease (IBD) is increasing worldwide. Recent epidemiological data indicate the potential beneficial effect of n-3 PUFAs in ulcerative colitis (UC) prevention, whereas consumption of a higher ratio of n-6 PUFAs versus n-3 PUFAs has been associated with an increased UC incidence...
December 5, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29205114/the-experience-with-biosimilars-of-infliximab-in-inflammatory-bowel-disease
#15
Pedro Avila-Ribeiro, Gionata Fiorino, Silvio Danese
BACKGROUND: biosimilars are similar versions of existing innovator biologic agents but with distinct manufacturing processes. They were approved in inflammatory bowel disease (IBD) by extrapolation of indication from rheumatic diseases. As regulatory requirements for biosimilar approval focus on pre-clinical evidence of similarity rather than clinical data on efficacy, safety and immunogenicity, it is critical to review clinical evidence supporting their use in IBD in order to overcome reluctance from patients and clinicians alike...
December 3, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29204064/vaccinations-in-immunosuppressive-dependent-pediatric-inflammatory-bowel-disease
#16
Huyen-Tran Nguyen, Phillip Minar, Kimberly Jackson, Patricia C Fulkerson
AIM: To determine the vaccination rates in pediatric immunosuppression-dependent inflammatory bowel disease (IBD) and review the safety and efficacy of vaccinations in this population. METHODS: The electronic medical records from October 2009 to December 2015 of patients diagnosed with IBD at 10 years of age or younger and prescribed anti-tumor necrosis factor alpha (anti-TNF-α) therapy were reviewed for clinical history, medication history, vaccination history, and hepatitis B and varicella titers...
November 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29203225/mucosal-healing-and-long-term-outcomes-of-patients-with-inflammatory-bowel-diseases-receiving-clinic-based-vs-trough-concentration-based-dosing-of-infliximab
#17
Lieven Pouillon, Marc Ferrante, Gert Van Assche, Paul Rutgeerts, Maja Noman, João Sabino, Niels Vande Casteele, Ann Gils, Séverine Vermeire
BACKGROUND & AIMS: The trough concentration adapted infliximab treatment (TAXIT) trial demonstrated that maintaining infliximab trough concentrations at 3-7 μg/mL is most effective at inducing remission in patients with inflammatory bowel diseases (IBD), with fewer flares than clinic-based dosing. We performed a follow-up analysis of study participants to explore the correlation between trough dosing strategy and mucosal healing, continued infliximab use, and rates of hospitalization, surgery, and steroid use...
December 1, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29197117/addition-of-allopurinol-for-altering-thiopurine-metabolism-to-optimize-therapy-in-patients-with-inflammatory-bowel-disease
#18
Geoffrey C Wall, Hamid Muktar, Cassandra Effken, Pramod B Mahajan
Thiopurine drugs, including azathioprine and 6-mercaptopurine, are used commonly in patients with inflammatory bowel disease for maintenance of remission. Although generally well tolerated, adverse effects lead to discontinuation in a significant minority of patients. Pharmacogenomic studies have suggested that metabolic breakdown of azathioprine in an individual is genetically determined. Coupled with the fact that certain thiopurine metabolites, notably 6-thioguanine nucleotide and 6-methylmercaptopurine, are associated with antiinflammatory effects and adverse effects, respectively, some investigators have examined intentionally shunting the metabolism of azathioprine toward increasing 6-thioguanine nucleotide levels by using low doses of the xanthine oxidoreductase inhibitor allopurinol to improve efficacy and decrease toxicity of azathioprine in patients with inflammatory bowel disease...
December 1, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/29191255/resveratrol-and-inflammatory-bowel-disease-the-evidence-so-far
#19
Sandra Nunes, Francesca Danesi, Daniele Del Rio, Paula Silva
Despite the fact that inflammatory bowel disease (IBD) has still no recognised therapy, treatments which have proven at least mildly successful in improving IBD symptoms include anti-inflammatory drugs and monoclonal antibodies targeting pro-inflammatory cytokines. Resveratrol, a natural (poly)phenol found in grapes, red wine, grape juice and several species of berries, has been shown to prevent and ameliorate intestinal inflammation. Here, we discuss the role of resveratrol in the improvement of inflammatory disorders involving the intestinal mucosa...
December 1, 2017: Nutrition Research Reviews
https://www.readbyqxmd.com/read/29183720/contemporary-applications-of-fecal-microbiota-transplantation-to-treat-intestinal-diseases-in-humans
#20
REVIEW
Christopher Staley, Alexander Khoruts, Michael J Sadowsky
The intestinal microbiota comprise an important organ that plays a vital role in host digestion, development, energy maintenance, hemostasis, and immunity. Disruption of the gut microbial community due to diet, lifestyle, or antibiotic exposure increases susceptibility to chronic infection and disease. Fecal microbiota transplantation (FMT) involves the transfer of gut microbiota from a healthy donor to a patient in order to restore normal diversity and function of the microbial community. This method has become a well established alternative therapy for the treatment of recurrent Clostridium difficile infection...
November 25, 2017: Archives of Medical Research
keyword
keyword
74383
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"